Edition:
United States

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

10.57USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$10.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
89,725
52-wk High
$17.11
52-wk Low
$5.07

Latest Key Developments (Source: Significant Developments)

Savara Reports Q4 Loss Per Share $0.23
Wednesday, 14 Mar 2018 04:05pm EDT 

March 14 (Reuters) - Savara Inc ::SAVARA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.23.Q4 EARNINGS PER SHARE VIEW $-0.26 -- THOMSON REUTERS I/B/E/S.  Full Article

Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S.
Monday, 12 Feb 2018 08:00am EST 

Feb 12 (Reuters) - Savara Inc ::SAVARA ANNOUNCES IND APPROVAL FOR EXPANSION OF MOLGRADEX PHASE 3 STUDY INTO U.S..SAVARA - ANTICIPATE THAT TOP LINE RESULTS FOR MOLGRADEX PHASE 3 STUDY WILL BE AVAILABLE IN Q2 OF 2019.  Full Article

Savara Inc - Development Award Raised to $6.7 Mln - Sec Filing
Thursday, 30 Nov 2017 06:34am EST 

Nov 30 (Reuters) - Savara Inc ::SAVARA- ON NOV 28 ENTERED INTO AMENDMENT EFFECTIVE SEPT 30,TO RESEARCH PROGRAM AWARD LETTER AGREEMENT BETWEEN CO, CYSTIC FIBROSIS FOUNDATION THERAPEUTICS.SAVARA INC - UNDER AMENDMENT, AMOUNT OF DEVELOPMENT AWARD AVAILABLE TO SAVARA WAS INCREASED BY $5 MILLION TO AN AGGREGATE OF $6.7 MILLION - SEC FILING.  Full Article

Savara ‍Received $5 Mln Award For Development Of Aerovanc​
Wednesday, 29 Nov 2017 08:00am EST 

Nov 29 (Reuters) - Savara Inc ::SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​.  Full Article

Savara posts Q3 loss per share $0.28
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Savara Inc :Savara reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.28.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Anticipating complete enrollment in molgradex phase 3 impala study in q1 2018​.Initiating phase 2A study of Molgradex for treatment of NTM in early 2018​.Expecting top-line results from aironite phase 2 indie study in h1 2018​.Research and development expenses were $5.0 million for three-months ended September 30, 2017, compared with $2.1 million for Q3 of 2016​.  Full Article

SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Wednesday, 25 Oct 2017 09:34am EDT 

Oct 25 (Reuters) - Savara Inc ::SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAVARA INC - ‍PRICES UNDERWRITTEN PUBLIC OFFERING OF 5.25 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $7.85 PER SHARE​.  Full Article

Savara announces proposed public offering of common stock
Tuesday, 24 Oct 2017 04:06pm EDT 

Oct 24 (Reuters) - Savara Inc :Savara announces proposed public offering of common stock.  Full Article

Savara reports completion of enrollment
Wednesday, 18 Oct 2017 08:00am EDT 

Oct 18 (Reuters) - Savara Inc ::Savara reports completion of enrollment in phase 2 clinical trial of aironite for the treatment of hfpef.Savara Inc - ‍expects that top-line results from indie-hfpef study will be available in first half of 2018​.  Full Article

Savara reports Q2 loss per share $0.90
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Savara Inc :Savara reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.90.Savara Inc - ‍On track to complete enrollment in molgradex phase 3 impala study in Q1 2018​.  Full Article

Savara reports positive interim results from a 50-patient open-label phase 2 study of aironite
Tuesday, 11 Jul 2017 08:00am EDT 

July 11 (Reuters) - Savara Inc ::Savara Inc reports positive interim results from an ongoing 50-patient open-label phase 2 study of aironite in patients with pulmonary hypertension.Says in 41 patients enrolled to date in study, administration of aironite significantly improved multiple hemodynamic measures.Savara Inc - most pronounced improvements seen in patients with pulmonary hypertension due to heart failure with preserved ejection fraction.Savara Inc - Aironite significantly lowered pulmonary artery pressures and significantly increased pulmonary arterial compliance.Savara Inc - Aironite was generally well-tolerated and no significant safety concerns were identified, supporting primary safety outcome of study.  Full Article

BRIEF-Savara Reports Q1 Loss Per Share $0.88

* SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE